Clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy - Scientific guideline
Table of contents
This document provides guidance for the evaluation of products used to reduce the risk of infection, caused by neutropenia induced by cytotoxic chemotherapy or by myeloablative therapy preceding bone marrow transplantation.
Keywords: Growth factors, myelosuppressive therapy, myeloablative therapy
-
List item
Overview of comments on guideline on clinical trials with haemopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy (CPMP/EWP/555/95 Rev 1) (PDF/74.88 KB)
First published: 22/03/2007
Last updated: 22/03/2007
EMEA/CHMP/EWP/506296/2007 -
List item
Draft guideline on clinical trials with haemopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy (PDF/60.21 KB)
Draft: consultation closed
First published: 27/04/2006
Last updated: 27/04/2006
CPMP/EWP/555/95 Rev 1